ClinicalTrials.gg
TerminatedNCT03689244SELECTUpdated Jun 21, 2024Results posted

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

A Phase 3 interventional study of Selexipag and Placebo in Chronic Thromboembolic Pulmonary Hypertension, sponsored by Actelion. Terminated at 162 sites in 31 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study did not demonstrate efficacy on the primary endpoint, PVR vs. placebo at wk 20 at a planned interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypertension, Pulmonary by Johnson & Johnson — 1 open to participants now, 2 under way, 2 of them phase 3. Hypertension, Pulmonary · Johnson & Johnson.

Enrollment
9th of 27
128 · median 67
Started
2019
with 2 others
Phase 3
13 of 29
1 open now
Registered
21st of 29
by date

Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 3, and was the 21st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 29 studies in Hypertension, Pulmonary by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypertension, Pulmonary by Johnson & Johnson, or all of them as a file.
02

Study summary

Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in participants with inoperable or persistent/recurrent CTEPH.

Read the detailed description

Participants will be recruited in two sequential cohorts: approximately the first 90 randomized participants will undergo a right heart catheterization (RHC) (and left heart catheterization LHC, if needed) with measurement of pulmonary vascular resistance (PVR) at Week 20 and will constitute the hemodynamic cohort; the remaining participants will constitute the non-hemodynamic cohort; who do not require a post-baseline hemodynamic assessment. They will undergo the same overall study assessments as the hemodynamic cohort excepted for RHC at Week 20.

03

Conditions studied

  • Chronic Thromboembolic Pulmonary Hypertension

Keywords

  • CTEPH
  • selexipag
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Signed and dated form
  • Male and female participants from greater than or equal to (>) 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and less then or equal to (\<=85) years old at Screening (Visit 1)
  • With established diagnosis of inoperable CTEPH (i.e., technically non-operable) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA) and/or balloon pulmonary angioplasty (BPA), as confirmed by the corresponding adjudication committee
  • With pulmonary hypertension (PH) in WHO FC I-IV.
  • Participant able to perform the 6-minute walk test (6MWT) with a minimum distance of 100 m and a maximum distance of 450 m at screening visit.
  • Women of must have a negative pregnancy test at screening and randomization and must agree to undertake monthly urine pregnancy tests, and to use a reliable method of from screening visit up to at least 30 days after study treatment discontinuation. If a hormonal contraceptive is chosen it must be taken for at least 1 month prior to randomization.

Main Exclusion Criteria:

  • Planned or current treatment with another treatment up to 3 months prior to randomization.
  • Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
  • Known concomitant life-threatening disease with a \< 12 months.
  • Planned balloon pulmonary angioplasty within 26 weeks after randomization.
  • Change in dose or initiation of new PH-specific therapy within 90 days prior to the baseline RHC (and LHC, if needed) qualifying for enrollment for the hemodynamic cohort and within 90 days prior to randomization (Visit 2) for the non-hemodynamic cohort
  • Treatment with prostacyclin (epoprostenol), prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) or prostacyclin receptor agonists (i.e., selexipag) within 90 days prior to randomization (visit 2) except those given at vasodilator testing during RHC
  • Change in dose or initiation of new diuretics and/or calcium channel blockers within 1 week prior to baseline RHC (and LHC, if needed)
  • Any co-morbid condition that may influence the ability to perform a reliable and reproducible 6MWT, including use of walking aids (cane, walker, etc).
  • Any other criteria as per selexipag Summary of Product Characteristics (SmPC).
  • Exclusion criteria related to comorbidities: severe coronary heart disease or unstable angina as assessed by the investigator; mocardial infarction within the last 6 months prior to or during Screening; decompensated cardiac failure if not under close supervision; severe arrhythmias as assessed by the investigator; cerebrovascular events (example , stroke) within the last 3 months prior to or during screening; congenital or acquired valvular defects with myocardial function disorders not related to pulmonary hypertension. (PH); known or suspicion of pulmonary veno-occlusive disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Selexipag DB

    During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).

    Drug: Selexipag

  • Placebo comparator
    Placebo DB

    During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.

    Drug: Placebo

  • Experimental
    Selexipag OL

    All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.

    Drug: Selexipag

Interventions

  • oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration

    Also known as: ACT-293987, JNJ-67896049

  • DrugPlacebo

    Oral tablets without active compound

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20

    Change from baseline in PVR at Week 20 was reported. PVR was measured by accessing the vessel either from right heart catheterization or left heart catheterization, if required. Change from baseline in PVR was measured as percent ratio of post treatment value (Week 20) to pre-treatment value (baseline).

    Time frame: Baseline (Day 1, pre-dose), within 2 to 5 hours post-dose on Week 20

07

Results

Posted Aug 9, 2023
Limitations and caveats
Failure to meet success on the primary outcome measure led to termination of the study for futility and thus the pre-planned testing hierarchy was no longer applicable, and all efficacy analyses other than the primary endpoint (PVR) were exploratory.

Participant flow

Double Blind Period (Up to 27.7 Months)
Participant flow — Double Blind Period (Up to 27.7 Months)
MilestoneDouble-blind Period: PlaceboDouble-blind Period: SelexipagOpen Label Period: Selexipag (Ex-Placebo)Open Label Period: Selexipag (Ex-Selexipag)
Started646400
Completed9600
Not completed555800
Withdrew: Withdrawal by subject7800
Withdrew: Other1100
Withdrew: Sponsor decision444700
Withdrew: Death1000
Withdrew: Physician decision2200
Open Label Period (Up to 20.8 Months)
Participant flow — Open Label Period (Up to 20.8 Months)
MilestoneDouble-blind Period: PlaceboDouble-blind Period: SelexipagOpen Label Period: Selexipag (Ex-Placebo)Open Label Period: Selexipag (Ex-Selexipag)
Started0096
Completed0000
Not completed0096
Withdrew: Withdrawal by subject0010
Withdrew: Physician decision0010
Withdrew: Sponsor decision0076

Outcome measures

PrimaryChange From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20

Change from baseline in PVR at Week 20 was reported. PVR was measured by accessing the vessel either from right heart catheterization or left heart catheterization, if required. Change from baseline in PVR was measured as percent ratio of post treatment value (Week 20) to pre-treatment value (baseline).

Time frame:
Baseline (Day 1, pre-dose), within 2 to 5 hours post-dose on Week 20
Reported as:
Geometric least squares mean · Percent ratio
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20
Percent ratioDouble-blind Period: PlaceboDouble-blind Period: Selexipag
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 2089.52 (81.78 to 97.99)85.15 (77.97 to 92.99)
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Selexipag · ANCOVA · p = 0.412 · Ratio of geometric ls mean: 0.95 · 95% CI 0.84 to 1.07

Adverse events

Collected over For DB period: from first DB dose up to EDBT (that is, up to 27.7 months) and for OL extension period: from first OL dose up to 30 days after the last OL dose (that is, up to 21.8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Period: Placebo2/64 (3.1%)16/64 (25%)45/64 (70.3%)
Double-blind Period: Selexipag3/64 (4.7%)9/64 (14.1%)60/64 (93.8%)
Open Label Period: Selexipag (Ex-Placebo)0/9 (0%)0/9 (0%)9/9 (100%)
Open Label Period: Selexipag (Ex-Selexipag)0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDouble-blind Period: PlaceboDouble-blind Period: SelexipagOpen Label Period: Selexipag (Ex-Placebo)Open Label Period: Selexipag (Ex-Selexipag)
Viral InfectionInfections and infestations0/640/640/91/6
Right Ventricular FailureCardiac disorders3/645/640/90/6
Acute Kidney InjuryRenal and urinary disorders2/641/640/90/6
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/640/640/90/6
Iron Deficiency AnaemiaBlood and lymphatic system disorders0/641/640/90/6
Atrial FlutterCardiac disorders1/640/640/90/6
Atrioventricular Block Second DegreeCardiac disorders1/640/640/90/6
Supraventricular TachycardiaCardiac disorders0/641/640/90/6
Discoloured VomitGastrointestinal disorders1/640/640/90/6
Catheter Site HaematomaGeneral disorders1/640/640/90/6
Most frequent other events
Showing 10 of 41
Most frequent other events
EventDouble-blind Period: PlaceboDouble-blind Period: SelexipagOpen Label Period: Selexipag (Ex-Placebo)Open Label Period: Selexipag (Ex-Selexipag)
HeadacheNervous system disorders14/6436/646/92/6
DiarrhoeaGastrointestinal disorders9/6438/645/91/6
MyalgiaMusculoskeletal and connective tissue disorders5/647/644/90/6
NauseaGastrointestinal disorders4/6417/643/91/6
VomitingGastrointestinal disorders1/6411/643/91/6
ArthralgiaMusculoskeletal and connective tissue disorders4/6414/643/91/6
Pain in JawMusculoskeletal and connective tissue disorders2/6416/642/90/6
Covid-19Infections and infestations4/645/642/90/6
DizzinessNervous system disorders7/648/642/90/6
Pain in ExtremityMusculoskeletal and connective tissue disorders4/6413/641/91/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
<=18 years000
Between 18 and 65 years243660
>=65 years402868
Age, Continuous
Age, Continuous(years)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
Mean64 ± 13.2262 ± 14.3863 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
Female474693
Male171835
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
Hispanic or Latino10818
Not Hispanic or Latino5455109
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
American Indian or Alaska Native101
Asian12719
Black or African American325
Native Hawaiian or Other Pacific Islander000
White465298
More than one race000
Unknown or Not Reported011
Other224
Region of Enrollment
Region of Enrollment(Participants)Double-blind Period: PlaceboDouble-blind Period: SelexipagTotal
ARGENTINA022
AUSTRALIA134
BELGIUM011
BRAZIL5611
BULGARIA134
CANADA011
CHINA022
CZECH REPUBLIC123
DENMARK437
GERMANY6915
HUNGARY011
ISRAEL202
ITALY235
MEXICO415
POLAND224
PORTUGAL516
RUSSIAN FEDERATION437
SLOVAKIA011
SOUTH KOREA729
SPAIN101
SWEDEN011
TAIWAN112
THAILAND426
TURKEY448
UKRAINE011
UNITED KINGDOM5611
UNITED STATES538
08

Study locations

162 sites
  • University of California San Diego Medical Center
    La Jolla, California 92037, United States
  • University of Southern California, Keck School of Medicine
    Los Angeles, California 90033, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Colorado Springs Pulmonary Consultants
    Colorado Springs, Colorado 80907, United States
  • South Denver Cardiology Associates PC
    Littleton, Colorado 80120, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32259, United States
  • Piedmont Healthcare
    Atlanta, Georgia 30309, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Chicago Hospitals - Chicago
    Chicago, Illinois 60637, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48912, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • St. Mary's Cardiology
    Reno, Nevada 89503, United States
  • University of New Mexico Clinical & Translational Science Center
    Albuquerque, New Mexico 87131, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140-5103, United States
  • Allegheny
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano
    Plano, Texas 75093, United States
  • Intermountain Medical Center
    Murray, Utah 84175, United States
  • University of Utah Cardiovascular Center
    Salt Lake City, Utah 84132, United States
  • Medical College of Wisconsin Froedtert Hospital
    Milwaukee, Wisconsin 53211, United States
  • Aurora Saint Lukes Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Sanatorio de la Trinidad Mitre
    Buenos Aires, C1039AAO, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, 1199ABB, Argentina
  • Sanatorio Ramon Cereijo
    Caba, C1048AAN, Argentina
  • Instituto de Cardiología y Cirugía Cardiovascular - Fundación Favaloro
    Caba, C1093AAS, Argentina
  • Hospital General de Agudos Dr Cosme Argerich
    Caba, C1155AHD, Argentina
  • Hospital Britanico de Buenos Aires
    Caba, C1280AEB, Argentina
  • Centro Médico Dra. De Salvo
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • Queensland Lung Transplant Service
    Chermside, 4032, Australia
  • St Vincent's hospital
    Darlinghurst, 2010, Australia
  • Pulmonary Arterial Hypertension Clinic
    Hobart, 7000, Australia
  • The Alfred Hospital
    Melbourne, 3004, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Ordensklinikum Linz GmbH Elisabethinen
    Linz, 4020, Austria
  • Medical University Vienna
    Vienna, 1090, Austria
  • ULB Hôpital Erasme
    Brussels, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Universidade Federal De Minas Gerais - Hospital das Clínicas
    Belo Horizonte, 30130-100, Brazil
  • Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa
    Belo Horizonte, 30441-070, Brazil
  • Fundacao para o Desenvolvimento Medico Hospitalar (UNESP Botucatu)
    Botucatu, 18618-686, Brazil
  • Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes
    Fortaleza, 60840-285, Brazil
  • Universidade Federal de Goias - Hospital das Clinicas da UFG
    Goiania, 74605-020, Brazil
  • Irmandade Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90020-090, Brazil
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-003, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
    Porto Alegre, 90610-000, Brazil
  • Fundacao do ABC - Centro Universitario FMABC
    Santo Andre, 09060-870, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
    Sao Paulo, 04037-003, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    Sao Paulo, 05403-000, Brazil
  • UMHAT 'Heart and Brain Center for Excellence'
    Pleven, 5800, Bulgaria
  • National Cardiology Hospital
    Sofia, 1392, Bulgaria
  • University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD
    Sofia, 1750, Bulgaria
  • University Of Calgary - Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Institut Universitaire De Cardiologie Et De Pneumologie De Québec
    Quebec, G1V 4G5, Canada
  • Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC)
    Beijing, 100730, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • The General Hospital of Northern Theater Command
    Shenyang, 110000, China
  • Shengjing Hospital Of China Medical University
    Shenyang, 110022, China
  • Shanxi Cardiovascular Hospital
    Taiyuan, 030001, China
  • Tianjin Medical University General Hospital
    Tian Jin, 300052, China
  • General University Hospital II.department of Internal Medicine-cardiology and angiology
    Praha 2, 128 08, Czechia
  • Århus Universitetshospital, Skejby, Hjertemedicinsk Afdeling B
    Arhus, 8200, Denmark
  • Rigshospitalet Kardiologisk Klinisk
    Copenhagen, 2100, Denmark
  • Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie
    Dresden, 01307, Germany
  • Universitätsklinikum Giessen Medizinische Klinik Und Poliklinik Ii, Pneumologie
    Giessen, 35392, Germany
  • Universität Greifswald - Klinik Für Innere Medizin Bereich Pneumologie/Infektiologie
    Greifswald, 17475, Germany
  • Universitätsklinikum Hamburg-Eppendorf - Pneumologie
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie
    Hannover, 30625, Germany
  • Thoraxklinik am Universitatsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Universitätskliniken des Saarlandes / Medizinische Klinik und Poliklinik, Innere Medizin V
    Homburg/Saar, 66421, Germany
  • Universitätsklinikum Leipzig Medizinischen Klinik und Poliklinik I, Abteilung für Pneumologie
    Leipzig, 04103, Germany
  • Klinikum Würzburg Mitte gGmbH Standort Missioklinik
    Würzburg, 97074, Germany
  • Semmelweis Egyetem,Pulmonológiai Klinika
    Budapest, 1083, Hungary
  • Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály
    Budapest, 1096, Hungary
  • Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7624, Hungary
  • Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő
    Szeged, 6720, Hungary
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, 4941492, Israel
  • The Chaim Sheba Medical Center
    Tel-Hashomer, 5265601, Israel
  • Azienda Ospedaliera Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Policlinico Umberto I
    Roma, 00161, Italy
  • Ospedale di Cattinara - Struttura complessa di Pneumologia
    Trieste, 34149, Italy
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of

Showing the first 100 of 162 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Actelion is a Janssen pharmaceutical company of Johnson \& Johnson. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jun 2022, 40 months.

Results were first posted in Aug 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2018
First posted
Sep 28, 2018
StartActual
Jan 23, 2019
Primary completionActual
Jun 7, 2022
CompletionActual
Jun 7, 2022
Results first posted
Aug 9, 2023
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03689244
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 28, 2018
Start date
Jan 23, 2019
Primary completion
Jun 7, 2022
Completion
Jun 7, 2022
Results posted
Aug 9, 2023
Last update
Jun 21, 2024

Study contacts

Julian Borissoff, MD, PhD
study director · Actelion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion